The Frequency ofBRAFMutation in Very Small Papillary Thyroid Carcinomas

Background : Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and BRAF (V600E) is the most frequent genetic alteration in PTCs. The aim of this study was to investigate the frequency of BRAF mutation, especially in very small PTCs. Methods : We analyzed the presence of the BRAF mutation in PTCs in subgroups defined by tumor size (0.5 cm intervals). Results : Of 140 patients, 85 (60.7%) showed a BRAF mutation. The frequency of BRAF mutation in the subgroup was: 45/70 (64.3%) in tumors less than 0.5 cm in size, 18/28 (64.3%) in 0.6-1 cm tumors, 10/22 (45.5%) in 1.1-1.5 cm tumors, and 12/20 (60.0%) in 1.6-2 cm tumors. There was no statistically significant association between BRAF mutation and tumor size (p = 0.44). Similarly, BRAF mutation was not statistically related to age, sex, stage, perithyroidal extension or lymph node metastasis. On multivariate logistic regression analysis, tumor sizes larger than 0.5 cm were associated with lymph node metastasis (odds ratio, 3.79; 95% confidence interval, 1.81 to 7.91; p

[1]  D. Heo,et al.  Differential effects between cyclooxygenase‐2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines , 2010, Head & neck.

[2]  Y. Youn,et al.  Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings , 2009, Head & neck.

[3]  Eun-Kyung Kim,et al.  Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. , 2009, Radiology.

[4]  Ji Soo Kim,et al.  Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. , 2009, Thyroid : official journal of the American Thyroid Association.

[5]  H. Min,et al.  Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma , 2009 .

[6]  M. Gao,et al.  Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma , 2009, Annals of Surgical Oncology.

[7]  M. Hočevar,et al.  Papillary thyroid microcarcinoma: Prognostic factors and treatment , 2008, Journal of surgical oncology.

[8]  M. Santoro,et al.  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. , 2007, Thyroid : official journal of the American Thyroid Association.

[9]  N. O. Küçük,et al.  Treatment for Microcarcinoma of the Thyroid—Clinical Experience , 2007, Clinical nuclear medicine.

[10]  O. Sheils,et al.  Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model , 2007, Molecular cancer.

[11]  U. Löhrs,et al.  KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.

[12]  S. Y. Park,et al.  Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. , 2006, Cancer.

[13]  Tae Yong Kim,et al.  The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.

[14]  T. Giordano,et al.  Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.

[15]  E. Pearce,et al.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  Tae Yong Kim,et al.  The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma , 2005 .

[17]  G. Sakorafas,et al.  Papillary thyroid microcarcinoma: a surgical perspective. , 2005, Cancer treatment reviews.

[18]  Kyung-Hee Kim,et al.  Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis , 2005, Pathology international.

[19]  Young Kun Kim,et al.  The Relationship between the BRAF Mutations in Thyroid Papillary Carcinomas and the Prognostic Factors , 2005 .

[20]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[21]  P. Argani,et al.  The V599E BRAF mutation is uncommon in biliary tract cancers , 2004, Modern Pathology.

[22]  Kyung-Hee Kim,et al.  Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. , 2004, Yonsei medical journal.

[23]  A. Pinchera,et al.  BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas , 2004 .

[24]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  V. Trovisco,et al.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.

[27]  A. Miyauchi,et al.  An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. , 2003, Thyroid : official journal of the American Thyroid Association.

[28]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[29]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[30]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[31]  D. Wynford‐Thomas,et al.  Sporadic ret‐rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? , 1998, The Journal of pathology.

[32]  L. Mariani,et al.  RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  B. J. Harrison,et al.  Papillary microcarcinoma of the thyroid gland , 1996, The British journal of surgery.